ArticleScientific reports2026
Transcriptional activation of PPP1R14C by KLF7 unleashes CDK1 activity to promote lung squamous cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lung squamous cell carcinoma (LUSC) is a lethal malignancy with a stark lack of targeted therapies, demanding the identification of novel molecular drivers. Here, we identify Protein Phosphatase 1 Regulatory Subunit 14C (PPP1R14C), an endogenous inhibitor of Protein Phosphatase 1 (PP1), as a pivotal oncogenic driver in LUSC. Integrative multi-omics analyses revealed consistent PPP1R14C overexpression in LUSC, which correlated with advanced tumor stage and poor patient survival. Mechanistically, we establish that the transcription factor KLF7 directly binds the PPP1R14C promoter to drive its expression. We demonstrate that PPP1R14C executes its pro-tumorigenic function by physically interacting with and inhibiting the PP1 catalytic subunit, thereby preventing the dephosphorylation and inactivation of CDK1. This sustained CDK1 hyperactivation fuels LUSC cell proliferation, invasion, and in vivo tumorigenesis. Critically, pharmacological inhibition of CDK1 completely abrogates the oncogenic phenotypes conferred by PPP1R14C. Our findings delineate a novel and actionable KLF7-PPP1R14C-PP1-CDK1 signaling cascade essential for LUSC pathogenesis, positioning PPP1R14C as both a prognostic biomarker and a compelling therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.